🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Central Serous Chorioretinopathy

    phase 2 small molecule completed

    1 trial

  2. Intravitreal injection of KH902

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Neovascular Age-related Macular Degeneration

    phase 2 mab completed

    1 trial

  3. Iomab-B

    Actinium Pharmaceuticals

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  4. Iparomlimab and Tuvonralimab Injection (QL1706)

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  5. Iparomlimab and Tuvonralimab Injection (QL1706)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  6. Iparomlimab and Tuvonralimab Injection in combination with TFOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. Iparomlimab and Tuvonralimab combined with lenvatinib and SOX

    The First People's Hospital of Lianyungang

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  8. Itacitinib, placebo of itacitinib 100mg

    Pari Pharma GmbH

    Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening

    phase 2 small molecule active

    1 trial

  9. Itepekimab

    Sanofi-aventis Healthcare Pty Ltd

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  10. Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial

  11. Ivacaftor 150 MG

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  12. Ixabepilone Injection

    Allarity Therapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  13. JNJ-54767414, Lenalidomide Accord 25 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 20 mg hard capsules, Dexamethasone Tablets BP 2.0mg, FLUDARABINE , Lenalidomide Accord 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Accord 15 mg hard capsules, JNJ-68284528, Lenalidomide Accord 5 mg hard capsules, Lenalidomide Accord 25 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Lenalidomide Accord 15 mg hard c

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  14. JNJ-80202135, JNJ-80202135, Saline, 0.9% Sodium Chloride Solution for Injection

    Janssen-Cilag International N.V.

    Active Idiopathic Inflammatory Myopathies (IIM)

    phase 2 small molecule active

    1 trial

  15. JNJ-88545223, JNJ-88545223, JNJ-88545223 Placebo

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 2 small molecule active

    1 trial

  16. JNJ-95475939, Placebo JNJ-95475939, Dupixent 300 mg solution for injection in pre-filled syringe

    Janssen-Cilag International N.V.

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  17. JTT-861, Placebo tablet for JTT-861

    Lacuna Pharma Pty Ltd

    Heart Failure (Heart Failure with Reduced Ejection Fraction)

    phase 2 small molecule active

    1 trial

  18. JY231 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Systemic Lupus Erythematosus (SLE)

    phase 2 small molecule active

    1 trial

  19. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ENFORTUMAB VEDOTIN

    Fondazione Telethon ETS

    Collecting Duct Carcinoma, Medullary Renal cell Carcinoma

    phase 2 small molecule active

    1 trial

  20. KEYTRUDA 25 mg/mL concentrate for solution for infusion, S095029/Sym025

    The George Institute

    MSI-H/dMMR Gastric cancer, MSI-H/dMMR Gastroesophageal-junction Cancer

    phase 2 small molecule active

    1 trial

  21. KEYTRUDA 25 mg/mL concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion.

    Ningbo Cancer Hospital

    METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)

    phase 2 small molecule active

    1 trial

  22. KVD001 Injection

    Kalvista Pharmaceuticals (Ireland) Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    2 trials

  23. Kapruvia 50 micrograms/mL solution for injection

    Fresenius Kabi Australia Pty Limited

    Pruritus, Chronic Kidney Diseases

    phase 2 small molecule active

    1 trial

  24. Kenacort-A 40, suspensie voor injectie 40 mg/ml, JNJ-81201887, Placebo to match Prednisone 20mg, 5mg, JNJ-81201887, Prednison acis 20 mg, Tabletten, Prednison acis 5 mg, Tabletten

    Janssen-Cilag International N.V.

    Geographic Atrophy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources